Lyra Therapeutics (LYRA) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$3.38.
- Lyra Therapeutics' EPS (Weighted Average and Diluted) rose 6273.43% to -$3.38 in Q3 2025 from the same period last year, while for Sep 2025 it was $53.0, marking a year-over-year increase of 21422.41%. This contributed to the annual value of -$1.43 for FY2024, which is 1401.81% down from last year.
- Per Lyra Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$3.38 for Q3 2025, which was up 6273.43% from -$5.51 recorded in Q2 2025.
- Lyra Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at -$0.13 for Q1 2025, and its period low was -$36.76 during Q2 2024.
- In the last 5 years, Lyra Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.47 in 2022 and averaged -$3.28.
- Per our database at Business Quant, Lyra Therapeutics' EPS (Weighted Average and Diluted) tumbled by 1011111.11% in 2024 and then soared by 8501.09% in 2025.
- Over the past 5 years, Lyra Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$1.05 in 2021, then soared by 55.14% to -$0.47 in 2022, then surged by 35.3% to -$0.3 in 2023, then soared by 44.59% to -$0.17 in 2024, then tumbled by 1904.6% to -$3.38 in 2025.
- Its last three reported values are -$3.38 in Q3 2025, -$5.51 for Q2 2025, and -$0.13 during Q1 2025.